Evidence map›Paper›PMID 26341077›Full record

ArticlePurinergic signalling2015

Paroxetine suppresses recombinant human P2X7 responses.

Phuong Dao-Ung, Kristen K Skarratt, Stephen J Fuller, Leanne Stokes

Open access · greenAbstract read
In one paragraph

Article in Purinergic signalling, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. P2YInternational journal of molecular sciences · 2020
    Article
  6. The P2X7 Receptor: Central Hub of Brain Diseases.Frontiers in molecular neuroscience · 2020
    Review
  7. P2X7 Receptor Signaling in Stress and Depression.International journal of molecular sciences · 2019
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Phuong Dao-UngSydney Medical School Nepean, University of Sydney, Nepean Hospital, Level 5 South Block, Derby Street, Penrith, NSW, 2750, Australia.
Kristen K SkarrattSydney Medical School Nepean, University of Sydney, Nepean Hospital, Level 5 South Block, Derby Street, Penrith, NSW, 2750, Australia.
Stephen J FullerSydney Medical School Nepean, University of Sydney, Nepean Hospital, Level 5 South Block, Derby Street, Penrith, NSW, 2750, Australia.
Leanne StokesSydney Medical School Nepean, University of Sydney, Nepean Hospital, Level 5 South Block, Derby Street, Penrith, NSW, 2750, Australia. l.stokes@uea.ac.uk.
Nepean Hospital · AUUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

P2X7 receptor (P2X7) activity may link inflammation to depressive disorders. Genetic variants of human P2X7 have been linked with major depression and bipolar disorders, and the P2X7 knockout mouse has been shown to exhibit anti-depressive-like behaviour. P2X7 is an ATP-gated ion channel and is a major regulator of the pro-inflammatory cytokine interleukin 1β (IL-1β) secretion from monocytes and microglia. We hypothesised that antidepressants may elicit their mood enhancing effects in part via modulating P2X7 activity and reducing inflammatory responses. In this study, we determined whether common psychoactive drugs could affect recombinant and native human P2X7 responses in vitro. Common antidepressants demonstrated opposing effects on human P2X7-mediated responses; paroxetine inhibited while fluoxetine and clomipramine mildly potentiated ATP-induced dye uptake in HEK-293 cells stably expressing recombinant human P2X7. Paroxetine inhibited dye uptake mediated by human P2X7 in a concentration-dependent manner with an IC(50) of 24 μM and significantly reduces ATP-induced inward currents. We confirmed that trifluoperazine hydrochloride suppressed human P2X7 responses (IC(50) of 6.4 μM). Both paroxetine and trifluoperazine did not inhibit rodent P2X7 responses, and mutation of a known residue (F 95L) did not alter the effect of either drug, suggesting neither drug binds at this site. Finally, we demonstrate that P2X7-induced IL-1β secretion from lipopolysaccharide (LPS)-primed human CD14(+) monocytes was suppressed with trifluoperazine and paroxetine.

Indexed as

AnimalsAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicAntipsychotic AgentsClomipramineDose-Response Relationship, DrugFluoxetineHumansInterleukin-1betaLipopolysaccharide ReceptorsMiceMonocytesParoxetinePurinergic P2X Receptor AgonistsPurinergic P2X Receptor AntagonistsRatsAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicAntipsychotic AgentsClomipramineFluoxetineIL1B protein, humanInterleukin-1betaLipopolysaccharide ReceptorsP2RX7 protein, humanParoxetinePurinergic P2X Receptor AgonistsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7Recombinant ProteinsTrifluoperazineAntidepressantATPFluoxetineInterleukin 1βP2X7ParoxetineTrifluoperazine

Identifiers

PMID26341077
PMCPMC4648795
OpenAlexW1674357349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.